MA43684A - Liraglutide utilisé dans le traitement de maladies rénales - Google Patents

Liraglutide utilisé dans le traitement de maladies rénales

Info

Publication number
MA43684A
MA43684A MA043684A MA43684A MA43684A MA 43684 A MA43684 A MA 43684A MA 043684 A MA043684 A MA 043684A MA 43684 A MA43684 A MA 43684A MA 43684 A MA43684 A MA 43684A
Authority
MA
Morocco
Prior art keywords
liraglutide
treatment
kidney diseases
kidney
diseases
Prior art date
Application number
MA043684A
Other languages
English (en)
Inventor
Søren Rasmussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA43684A publication Critical patent/MA43684A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043684A 2016-03-04 2017-03-03 Liraglutide utilisé dans le traitement de maladies rénales MA43684A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16158738 2016-03-04

Publications (1)

Publication Number Publication Date
MA43684A true MA43684A (fr) 2018-11-28

Family

ID=55484878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043684A MA43684A (fr) 2016-03-04 2017-03-03 Liraglutide utilisé dans le traitement de maladies rénales

Country Status (4)

Country Link
US (1) US20190091295A1 (fr)
CN (1) CN108883158A (fr)
MA (1) MA43684A (fr)
WO (1) WO2017149105A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056663C (fr) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Utilisation du dulaglutide pour reduire le risque d'evenement cardiovasculaire chez les patients atteints du diabete de type 2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
MXPA06005581A (es) * 2003-11-20 2006-08-11 Novo Nordisk As Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.

Also Published As

Publication number Publication date
US20190091295A1 (en) 2019-03-28
WO2017149105A1 (fr) 2017-09-08
CN108883158A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA50056A (fr) Procédés de traitement de tumeur
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
MA47558A (fr) Traitement de la fibrose
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
MA49248A (fr) Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome
MA47820A (fr) Traitement de la glycogénose de type iii
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA47408A (fr) Traitement du cancer
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
MA42999A (fr) Polythérapie pour le traitement de malignités
MA42930A (fr) Traitement de maladies neurodégénératives
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
MA52627A (fr) Traitement du cancer
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
DK3630164T3 (da) Dulaglutid til behandling af kronisk nyresygdom
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
MA41202A (fr) Copolymères polydiallymine réticulé pour le traitement du diabète de type 2